NTII Neurobiological Technologies (MM)

NTII Presentation at Redchip Scottsdale Investor Conference 2003 RICHMOND, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Neurobiological Tech Inc. announces the following webcast: What: NTII Presentation at Redchip Scottsdale Investor Conference 2003 When: 12/11/03 @ 11:30 a.m. Eastern Where: http://www.firstcallevents.com/service/ajwz393979257gf12.html How: Live over the Internet -- Simply log on to the web at the address above. Contact: Paul Freiman, President and CEO, +1-510-262-1730, or NTI is an emerging drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The Company's strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. The Company's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy and seeks partnerships with pharmaceutical and biotechnology companies to complete development and marketing of its product candidates. (Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/EN/default.asp and at least a 28.8 kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to .) http://www.firstcallevents.com/service/ajwz393979257gf12.htmlDATASOURCE: Neurobiological Tech Inc. CONTACT: Paul Freiman, President and CEO of Neurobiological Tech Inc, +1-510-262-1730, or Web site: http://www.ntii.com/

Copyright